Pfizer recently presented real-world evidence demonstrating a significant benefit for patients treated with Ibrance (palbociclib) combined with an aromatase inhibitor (AI) compared to AI...
Gilead and Dragonfly Therapeutics recently collaborated to advance several of Dragonfly’s novel natural killer (NK) cell engager-based immunotherapies for oncology and inflammation...
Eli Lilly and Company recently announced that patients in a Phase 3 trial who received its obesity drug, tirzepatide, lost up to 22.5% of their body weight.
The SURMOUNT-1 clinical trial...
Roche recently announced new three-year data of its study evaluating Evrysdi (risdiplam) in infants with symptomatic Type 1 spinal muscular atrophy (SMA).
The FIREFISH study evaluated the...
AstraZeneca recently announced plans to open a new drug research and development site at the heart of Cambridge, MA, for itself and Alexion’s new corporate headquarters.
The strategic center...
FDA recently expanded the approval for COVID-19 treatment, Veklury (remdesivir), to include pediatric patients 28 days of age and older weighing at least seven pounds.
The agency's decision...
FDA recently accepted AstraZeneca’s biologics license application (BLA) for its anti-CTLA4 antibody, tremelimumab, supporting the indication of a single primary dose of the drug added to Imfinzi...
Pfizer and Valneva recently reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.
The Phase 2 trial, VLA15-221, is the first clinical study with VLA15 that enrolled...
Sandoz recently launched its generic drug combination eyedrop, brimonidine tartrate/ timolol maleate ophthalmic solution 0.2%/0.5%, to lower eye pressure in patients with ocular...
Johnson & Johnson recently launched the J&J Satellite Center for Global Health Discovery (Satellite Center) to tackle the present and the rising threat of antimicrobial resistance (AMR) with a...
FDA recently accepted the New Drug Application (NDA) for GSK’s daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) to treat patients with anemia of chronic kidney...
Sanofi recently announced positive results from the Phase 1/2 clinical trial evaluating its Bruton's tyrosine kinase (BTK) inhibitor, rilzabrutinib, in adults with heavily pre-treated immune...
Moderna recently dosed the first patients in a Phase 1/2 study of its influenza mRNA vaccine candidates, mRNA-1020 and mRNA-1030.
The randomized, observer-blind trial will evaluate the safety,...
Sanofi recently launched its first-in-pharma Diversity, Equity, & Inclusion (DE&I) Board to encourage an inclusive and diverse culture that enables breakthrough innovations.
The...
Pfizer will acquire clinical-stage biopharmaceutical company ReViral to discover, develop, and commercialize novel antiviral respiratory syncytial virus (RSV) therapeutics.
ReViral’s...
FDA recently approved ViiV Healthcare’s fixed-dose combination of abacavir, dolutegravir, and lamivudine to treat pediatric patients with HIV-1.
The agency also approved the...
Sandoz recently expanded its strategic collaboration agreement with Ares Genetics (Ares) to drive cutting-edge digital solutions in the global fight against antimicrobial resistance (AMR).
The...
The Digital Medicine Society (DiMe), Anthem, Biogen, Eli Lilly & Company, Evidation, Janssen, Merck, Pfizer, and Savvy Co-op recently launched a toolkit of resources to support organizations...
FDA recently expanded the indication of the long-acting injectable HIV regimen, Cabenuva, to include virologically suppressed adolescents 12 years of age and older.
Johnson & Johnson and...
AstraZeneca recently announced that it will present new data underscoring its oncology treatment landscape through diverse early pipelines and novel drug combinations.
The company’s next...
